Contact
searchSearch
HMP Global

Drug Recalls

The Latest

News
Cemiplimab Injection Recalled Due to Lack of Sterility Assurance
08/27/2026
Rebecca Amrick
Libtayo (cemiplimab-rwlc) injection is under a voluntary Class II recall due to a lack of assurance of the product’s sterility, affecting 21 353 vials.
Libtayo (cemiplimab-rwlc) injection is under a voluntary Class II recall due to a lack of assurance of the product’s sterility, affecting 21 353 vials.
Libtayo (cemiplimab-rwlc)...
08/27/2026
Pharmacy Learning Network
News
Acamprosate Calcium Tablets Recalled Due to Failed Dissolution Specifications
08/27/2026
Rebecca Amrick
A voluntary Class II recall has been issued for acamprosate calcium tablets due to the product’s failure to meet dissolution specifications.
A voluntary Class II recall has been issued for acamprosate calcium tablets due to the product’s failure to meet dissolution specifications.
A voluntary Class II recall has...
08/27/2026
Pharmacy Learning Network
News
Morphine Injection Recalled Due to Labeling Mix-Up
08/27/2026
Rebecca Amrick
The US Food and Drug Administration (FDA) has issued a Class I recall for morphine sulfate injection due to a mistake in product labeling, affecting 625 500 syringes.
The US Food and Drug Administration (FDA) has issued a Class I recall for morphine sulfate injection due to a mistake in product labeling, affecting 625 500 syringes.
The US Food and Drug...
08/27/2026
Pharmacy Learning Network
News
Valsartan Tablets Recalled Due to Failed Dissolution Specifications
08/20/2026
Rebecca Amrick
Diovan (valsartan) tablets are under a voluntary Class II recall after failing to meet dissolution specifications.
Diovan (valsartan) tablets are under a voluntary Class II recall after failing to meet dissolution specifications.
Diovan (valsartan) tablets are...
08/20/2026
Pharmacy Learning Network
News
Clindamycin Palmitate Hydrochloride Recalled Due to the Presence of Foreign Substance
08/20/2026
Rebecca Amrick
A voluntary Class II recall has been issued for clindamycin palmitate hydrochloride oral solution due to the presence of foreign particles in the product.
A voluntary Class II recall has been issued for clindamycin palmitate hydrochloride oral solution due to the presence of foreign particles in the product.
A voluntary Class II recall has...
08/20/2026
Pharmacy Learning Network
News
Kian Pee Wan Capsules Recalled Due to Undeclared Drug Ingredients
08/20/2026
Rebecca Amrick
The US Food and Drug Administration (FDA) has issued a Class I recall for Kian Pee Wan capsules due to the presence of undeclared drug ingredients (dexamethasone and cyproheptadine), affecting 71 bottles.
The US Food and Drug Administration (FDA) has issued a Class I recall for Kian Pee Wan capsules due to the presence of undeclared drug ingredients (dexamethasone and cyproheptadine), affecting 71 bottles.
The US Food and Drug...
08/20/2026
Pharmacy Learning Network
News
Mirabegron Tablets Recalled Due to CGMP Deviations
08/13/2026
Rebecca Amrick
Mirabegron extended-release tablets are under a voluntary Class II recall after an N-nitroso mirabegron impurity was found in the product, violating Current Good Manufacturing Practice specifications.
Mirabegron extended-release tablets are under a voluntary Class II recall after an N-nitroso mirabegron impurity was found in the product, violating Current Good Manufacturing Practice specifications.
Mirabegron extended-release...
08/13/2026
Pharmacy Learning Network
News
Dicyclomine Hydrochloride Recalled Due to Empty Capsules
08/13/2026
Rebecca Amrick
A voluntary Class II recall has been issued for dicyclomine hydrochloride due to reports of empty capsules, affecting 6408 bottles.
A voluntary Class II recall has been issued for dicyclomine hydrochloride due to reports of empty capsules, affecting 6408 bottles.
A voluntary Class II recall has...
08/13/2026
Pharmacy Learning Network
News
Cyclophosphamide Injection Recalled Due to the Presence of Steel Particles
08/13/2026
Rebecca Amrick
The US Food and Drug Administration (FDA) has issued a Class I recall for cyclophosphamide injection due to the presence of steel particles, affecting 5541 vials.
The US Food and Drug Administration (FDA) has issued a Class I recall for cyclophosphamide injection due to the presence of steel particles, affecting 5541 vials.
The US Food and Drug...
08/13/2026
Pharmacy Learning Network
News
Dorzolamide and Timolol Ophthalmic Solution Recalled Due to Defective Containers
08/06/2026
Rebecca Amrick
Dorzolamide and timolol maleate ophthalmic solution is subject to a voluntary Class II recall after the firm received complaints about defective containers.
Dorzolamide and timolol maleate ophthalmic solution is subject to a voluntary Class II recall after the firm received complaints about defective containers.
Dorzolamide and timolol maleate...
08/06/2026
Pharmacy Learning Network
News
Azelaic Acid Gel Recalled Due to CGMP Deviations
08/06/2026
Rebecca Amrick
A voluntary Class II recall has been issued for azelaic acid gel due to Current Good Manufacturing Practice (CGMP) deviations, resulting from the product’s abnormal texture.
A voluntary Class II recall has been issued for azelaic acid gel due to Current Good Manufacturing Practice (CGMP) deviations, resulting from the product’s abnormal texture.
A voluntary Class II recall has...
08/06/2026
Pharmacy Learning Network

Newsfeed

News
Cemiplimab Injection Recalled Due to Lack of Sterility Assurance
08/27/2026
Rebecca Amrick
Libtayo (cemiplimab-rwlc) injection is under a voluntary Class II recall due to a lack of assurance of the product’s sterility, affecting 21 353 vials.
Libtayo (cemiplimab-rwlc) injection is under a voluntary Class II recall due to a lack of assurance of the product’s sterility, affecting 21 353 vials.
Libtayo (cemiplimab-rwlc)...
08/27/2026
Pharmacy Learning Network
News
Acamprosate Calcium Tablets Recalled Due to Failed Dissolution Specifications
08/27/2026
Rebecca Amrick
A voluntary Class II recall has been issued for acamprosate calcium tablets due to the product’s failure to meet dissolution specifications.
A voluntary Class II recall has been issued for acamprosate calcium tablets due to the product’s failure to meet dissolution specifications.
A voluntary Class II recall has...
08/27/2026
Pharmacy Learning Network
News
Morphine Injection Recalled Due to Labeling Mix-Up
08/27/2026
Rebecca Amrick
The US Food and Drug Administration (FDA) has issued a Class I recall for morphine sulfate injection due to a mistake in product labeling, affecting 625 500 syringes.
The US Food and Drug Administration (FDA) has issued a Class I recall for morphine sulfate injection due to a mistake in product labeling, affecting 625 500 syringes.
The US Food and Drug...
08/27/2026
Pharmacy Learning Network
News
Valsartan Tablets Recalled Due to Failed Dissolution Specifications
08/20/2026
Rebecca Amrick
Diovan (valsartan) tablets are under a voluntary Class II recall after failing to meet dissolution specifications.
Diovan (valsartan) tablets are under a voluntary Class II recall after failing to meet dissolution specifications.
Diovan (valsartan) tablets are...
08/20/2026
Pharmacy Learning Network
News
Clindamycin Palmitate Hydrochloride Recalled Due to the Presence of Foreign Substance
08/20/2026
Rebecca Amrick
A voluntary Class II recall has been issued for clindamycin palmitate hydrochloride oral solution due to the presence of foreign particles in the product.
A voluntary Class II recall has been issued for clindamycin palmitate hydrochloride oral solution due to the presence of foreign particles in the product.
A voluntary Class II recall has...
08/20/2026
Pharmacy Learning Network
News
Kian Pee Wan Capsules Recalled Due to Undeclared Drug Ingredients
08/20/2026
Rebecca Amrick
The US Food and Drug Administration (FDA) has issued a Class I recall for Kian Pee Wan capsules due to the presence of undeclared drug ingredients (dexamethasone and cyproheptadine), affecting 71 bottles.
The US Food and Drug Administration (FDA) has issued a Class I recall for Kian Pee Wan capsules due to the presence of undeclared drug ingredients (dexamethasone and cyproheptadine), affecting 71 bottles.
The US Food and Drug...
08/20/2026
Pharmacy Learning Network
News
Mirabegron Tablets Recalled Due to CGMP Deviations
08/13/2026
Rebecca Amrick
Mirabegron extended-release tablets are under a voluntary Class II recall after an N-nitroso mirabegron impurity was found in the product, violating Current Good Manufacturing Practice specifications.
Mirabegron extended-release tablets are under a voluntary Class II recall after an N-nitroso mirabegron impurity was found in the product, violating Current Good Manufacturing Practice specifications.
Mirabegron extended-release...
08/13/2026
Pharmacy Learning Network
News
Dicyclomine Hydrochloride Recalled Due to Empty Capsules
08/13/2026
Rebecca Amrick
A voluntary Class II recall has been issued for dicyclomine hydrochloride due to reports of empty capsules, affecting 6408 bottles.
A voluntary Class II recall has been issued for dicyclomine hydrochloride due to reports of empty capsules, affecting 6408 bottles.
A voluntary Class II recall has...
08/13/2026
Pharmacy Learning Network
News
Cyclophosphamide Injection Recalled Due to the Presence of Steel Particles
08/13/2026
Rebecca Amrick
The US Food and Drug Administration (FDA) has issued a Class I recall for cyclophosphamide injection due to the presence of steel particles, affecting 5541 vials.
The US Food and Drug Administration (FDA) has issued a Class I recall for cyclophosphamide injection due to the presence of steel particles, affecting 5541 vials.
The US Food and Drug...
08/13/2026
Pharmacy Learning Network
News
Dorzolamide and Timolol Ophthalmic Solution Recalled Due to Defective Containers
08/06/2026
Rebecca Amrick
Dorzolamide and timolol maleate ophthalmic solution is subject to a voluntary Class II recall after the firm received complaints about defective containers.
Dorzolamide and timolol maleate ophthalmic solution is subject to a voluntary Class II recall after the firm received complaints about defective containers.
Dorzolamide and timolol maleate...
08/06/2026
Pharmacy Learning Network
PharmLaw
Walmart Reaches $50 Million Settlement Over Opioid Prescription Allegations
09/02/2026
Grace Taylor, MS, MA
Walmart has agreed to pay $50 million to resolve federal allegations that its pharmacies unlawfully filled thousands of opioid and other controlled substance prescriptions.
Walmart has agreed to pay $50 million to resolve federal allegations that its pharmacies unlawfully filled thousands of opioid and other controlled substance prescriptions.
Walmart has agreed to pay $50...
09/02/2026
Pharmacy Learning Network
News
Cemiplimab Injection Recalled Due to Lack of Sterility Assurance
08/27/2026
Rebecca Amrick
Libtayo (cemiplimab-rwlc) injection is under a voluntary Class II recall due to a lack of assurance of the product’s sterility, affecting 21 353 vials.
Libtayo (cemiplimab-rwlc) injection is under a voluntary Class II recall due to a lack of assurance of the product’s sterility, affecting 21 353 vials.
Libtayo (cemiplimab-rwlc)...
08/27/2026
Pharmacy Learning Network
News
Acamprosate Calcium Tablets Recalled Due to Failed Dissolution Specifications
08/27/2026
Rebecca Amrick
A voluntary Class II recall has been issued for acamprosate calcium tablets due to the product’s failure to meet dissolution specifications.
A voluntary Class II recall has been issued for acamprosate calcium tablets due to the product’s failure to meet dissolution specifications.
A voluntary Class II recall has...
08/27/2026
Pharmacy Learning Network
News
Morphine Injection Recalled Due to Labeling Mix-Up
08/27/2026
Rebecca Amrick
The US Food and Drug Administration (FDA) has issued a Class I recall for morphine sulfate injection due to a mistake in product labeling, affecting 625 500 syringes.
The US Food and Drug Administration (FDA) has issued a Class I recall for morphine sulfate injection due to a mistake in product labeling, affecting 625 500 syringes.
The US Food and Drug...
08/27/2026
Pharmacy Learning Network
PharmLaw
Monogram Health to Pay $2.4 Million to Settle Medicare Advantage False Claims Allegations
08/26/2026
Grace Taylor, MS, MA
Monogram Health has agreed to pay $2.4 million to settle federal allegations that unsupported diagnosis codes led to increased Medicare Advantage payments.
Monogram Health has agreed to pay $2.4 million to settle federal allegations that unsupported diagnosis codes led to increased Medicare Advantage payments.
Monogram Health has agreed to...
08/26/2026
Pharmacy Learning Network
News
Valsartan Tablets Recalled Due to Failed Dissolution Specifications
08/20/2026
Rebecca Amrick
Diovan (valsartan) tablets are under a voluntary Class II recall after failing to meet dissolution specifications.
Diovan (valsartan) tablets are under a voluntary Class II recall after failing to meet dissolution specifications.
Diovan (valsartan) tablets are...
08/20/2026
Pharmacy Learning Network
News
Clindamycin Palmitate Hydrochloride Recalled Due to the Presence of Foreign Substance
08/20/2026
Rebecca Amrick
A voluntary Class II recall has been issued for clindamycin palmitate hydrochloride oral solution due to the presence of foreign particles in the product.
A voluntary Class II recall has been issued for clindamycin palmitate hydrochloride oral solution due to the presence of foreign particles in the product.
A voluntary Class II recall has...
08/20/2026
Pharmacy Learning Network
News
Kian Pee Wan Capsules Recalled Due to Undeclared Drug Ingredients
08/20/2026
Rebecca Amrick
The US Food and Drug Administration (FDA) has issued a Class I recall for Kian Pee Wan capsules due to the presence of undeclared drug ingredients (dexamethasone and cyproheptadine), affecting 71 bottles.
The US Food and Drug Administration (FDA) has issued a Class I recall for Kian Pee Wan capsules due to the presence of undeclared drug ingredients (dexamethasone and cyproheptadine), affecting 71 bottles.
The US Food and Drug...
08/20/2026
Pharmacy Learning Network
PharmLaw
AstraZeneca Challenges Illinois 340B Contract Pharmacy Law in Federal Court
08/19/2026
Hannah Musick
AstraZeneca has joined AbbVie and Novartis in challenging Illinois’ new 340B contract pharmacy law, adding to a growing national legal battle over state authority to regulate manufacturer distribution requirements and compliance data within...
AstraZeneca has joined AbbVie and Novartis in challenging Illinois’ new 340B contract pharmacy law, adding to a growing national legal battle over state authority to regulate manufacturer distribution requirements and compliance data within...
AstraZeneca has joined AbbVie...
08/19/2026
Pharmacy Learning Network
News
Mirabegron Tablets Recalled Due to CGMP Deviations
08/13/2026
Rebecca Amrick
Mirabegron extended-release tablets are under a voluntary Class II recall after an N-nitroso mirabegron impurity was found in the product, violating Current Good Manufacturing Practice specifications.
Mirabegron extended-release tablets are under a voluntary Class II recall after an N-nitroso mirabegron impurity was found in the product, violating Current Good Manufacturing Practice specifications.
Mirabegron extended-release...
08/13/2026
Pharmacy Learning Network

HMP Global Products

Events

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2026 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Terms of Use